# Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis

> **NCT01158183** · — · COMPLETED · sponsor: **Bayer** · enrollment: 226 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** BAY86-5046_Interferon-beta-1b

## Key facts

- **NCT ID:** NCT01158183
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2010-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01158183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01158183, "Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01158183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*